ESMO 2024 – Keytruda/Lenvima leap... up to a point
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.